It looks like you're new here. If you want to get involved, click one of these buttons!
If you can read this message, please contact us immediately at the following email address:
We'd like to communicate.
Results of the study showed more than twice as many patients were alive five years after receiving the tumor-treating fields (TTFields) treatment, along with chemotherapy, than those who were given just chemo.
"It's out of the box" in terms of how cancer is usually treated, and many doctors are skeptical of the therapy. It also comes with a price tag of $21,000 per month, according to Dr. Roger Stupp, a brain tumor expert at Northwestern University in Chicago, as cited by Medical Express.
"Patients like it. Doctors have more of a problem. They think it's weird," Dr Stupp told Medscape.
Stupp led the study, which involved about 80 centers worldwide and 695 patients, while at University Hospital Zurich in Switzerland, and presented the results Sunday at the American Association for Cancer Research meeting in Washington.
The study was aimed at improving survival in glioblastoma, the most aggressive and malignant primary brain tumor in adults. It required patients to wear the device for at least 18 hours a day while going about their usual routine.
“Our results demonstrate a proof-of-concept that this treatment modality actually works, and can prevent tumor cells from growing and dividing," Stupp told HealthDay.
While the device, named Optune, does not cure the cancer, patients who availed of the treatment experienced a 43 percent survival rate in the first two years, in comparison to 31 percent for standard chemotherapy treatments.
"The device is now impossible to ignore... it absolutely is an advance," said Dr. Andrew Lassman, brain tumor chief at the Columbia University Medical Center/New York-Presbyterian Hospital.